Biocryst Pharmaceuticals (BCRX) Interest & Investment Income (2010 - 2026)

Biocryst Pharmaceuticals (BCRX) has reported Interest & Investment Income for 17 consecutive years, with $2.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Interest & Investment Income fell 3.26% year-over-year to $2.4 million; the trailing twelve-month figure through Jun 2026 stood at $9.8 million (down 22.7% YoY), and the FY2025 full-year result was $10.7 million, down 27.65% from the prior year.
• Interest & Investment Income climbed to $2.4 million in Q2 2026 per BCRX's latest filing, from $2.3 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $4.5 million in Q4 2023 and bottomed at -$69000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $2.8 million across 5 years, with a median of $3.0 million in 2025.
• The widest YoY moves for Interest & Investment Income: up 19455.56% in 2022, down 365.38% in 2022.
• Over 5 years, Interest & Investment Income stood at $2.7 million in 2022, then jumped by 65.13% to $4.5 million in 2023, then decreased by 20.04% to $3.6 million in 2024, then declined by 19.05% to $2.9 million in 2025, then retreated by 15.78% to $2.4 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $2.4 million, $2.3 million, and $2.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.